Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
63 hedge funds and large institutions have $44.2M invested in Viracta Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 24 reducing their positions, and 17 closing their positions.
217% more call options, than puts
Call options by funds: $716K | Put options by funds: $226K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 69 → 63 (-6)
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
29% less capital invested
Capital invested by funds: $62.4M → $44.2M (-$18.2M)
63% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$1.99M |
| 2 |
Millennium Management
New York
|
+$901K |
| 3 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$761K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$616K |
| 5 |
E
Ergoteles
New York
|
+$443K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.04M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.51M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$792K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$698K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$475K |
VIRX Hedge Fund Activity: Q2 2022 in Review
63 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2022, worth a combined $44.2M — down 29% from $62.4M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of VIRX and 13 opened new positions — a net loss of 4 holders — while 24 trimmed existing stakes and 9 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $1.99M. The largest seller was BlackRock, cutting an estimated $5.04M.
- 63 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2022, down from 69 in Q1 2022.
- Funds reported $44.2M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2022, down 29% quarter-over-quarter.
- 13 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2022 and 17 closed out, a net change of -4 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2022 was Laurion Capital Management, an estimated $1.99M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $5.04M sold.
Based on aggregated 13F filings for Q2 2022.